Stockscreener 앱 받기
36.94
0.14%
-0.085
전일 마감가:
$37.02
열려 있는:
$36.91
하루 거래량:
1.09M
Relative Volume:
0.53
시가총액:
$7.62B
수익:
$2.09B
순이익/손실:
$424.88M
주가수익비율:
18.07
EPS:
2.0439
순현금흐름:
$447.20M
1주 성능:
-1.57%
1개월 성능:
+13.30%
6개월 성능:
-18.64%
1년 성능:
-20.87%
1일 변동 폭
$36.70
$37.13
1주일 범위
$36.23
$37.81
52주 변동 폭
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
36.95 | 7.64B | 2.09B | 424.88M | 447.20M | 2.0439 |
TMO
Thermo Fisher Scientific Inc
|
473.87 | 179.14B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
180.81 | 129.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
553.60 | 43.93B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
129.15 | 37.17B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.02 | 35.66B | 3.77B | 449.25M | 240.68M | 7.8556 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2026-03-13 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2026-01-22 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-04 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-12-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-10-17 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2024-06-27 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-07 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-09-12 | 개시 | Robert W. Baird | Outperform |
| 2023-05-23 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-18 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-01-18 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-10-15 | 재개 | Cowen | Market Perform |
| 2021-10-14 | 개시 | Redburn | Buy |
| 2021-07-14 | 다운그레이드 | Kepler | Buy → Hold |
| 2021-06-03 | 개시 | Goldman | Neutral |
| 2020-10-06 | 재개 | BofA Securities | Buy |
| 2020-09-28 | 업그레이드 | Kepler | Hold → Buy |
| 2020-08-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-08-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-08-14 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2020-08-14 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
| 2020-03-04 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-12-26 | 재개 | BofA/Merrill | Underperform |
| 2019-11-15 | 개시 | Stifel | Hold |
| 2019-11-14 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-11-14 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2019-11-14 | 업그레이드 | Kepler | Reduce → Hold |
| 2019-10-17 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-10-09 | 다운그레이드 | Kepler | Hold → Reduce |
| 2019-10-08 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2019-10-08 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2019-10-08 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
Qiagen Nv 주식(QGEN)의 최신 뉴스
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Release according to Article 40, Section 1 of the WpHG - TradingView
A Look at Qiagen NV (QGEN) After 4.2% Gain -- GF Value $52.66 vs Price $37.75 - GuruFocus
Qiagen N.V. stock (NL0012169213): focus on molecular diagnostics and steady demand drivers - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics player stays in focus after latest quarterly update - AD HOC NEWS
How Qiagen N.v. (QGEN) Affects Rotational Strategy Timing - Stock Traders Daily
Qiagen N.V. stock (NL0012169213): Diagnostic specialist updates investors after recent earnings - AD HOC NEWS
Evaluating Qiagen (NYSE:QGEN) After New Bundibugyo Ebolavirus Digital PCR Assays Catch Investor Attention - Sahm
Qiagen N.V. Common Shares (NY: QGEN - FinancialContent
Goldman Sachs Discloses 3.14% Voting Stake in QIAGEN - TipRanks
UBS reveals 3.04% voting stake in Qiagen after AFM filing - TipRanks
Qiagen reports 2.75% voting stake in its shares held by UBS Group - TipRanks
MFS reports 12.45M-share, 6.0% stake in QGEN (NYSE: QGEN) - Stock Titan
Qiagen (QGEN) Up 12.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QIAGEN Business Breakdown and Growth Drivers for 2026 - qz.com
Is Qiagen’s New Bundibugyo Assays Strategy Quietly Reframing Its Infectious Disease Tools Story (QGEN)? - Sahm
Is It Too Late to Buy Qiagen NV (QGEN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AlphaValue/Baader Europe Cuts Qiagen Price Target, Estimates Post FY26 Guidance Change - 富途牛牛
LVIP MFS International Growth Fund's Qiagen NV(LTS:0RLT) Holding History - GuruFocus
Qiagen N.V. stock (NL0012169213): Legal probe and Jefferies conference keep shares in focus - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Shares in focus after Jefferies conference appearance and law firm - AD HOC NEWS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Qiagen N.V.QGEN - Hastings Tribune
Qiagen N.V. stock (NL0012169213): Deutsche Bank reiterates Buy rating with USD 43 target - AD HOC NEWS
Qiagen (QGEN) Q1 2026 Earnings Transcript - AOL.com
QIAGEN NV : Deutsche Bank keeps its Buy rating - marketscreener.com
Qiagen N.V. (QGEN) Presents at Deutsche Bank German Corporate ConferenceSlideshow (NYSE:QGEN) 2026-06-01 - Seeking Alpha
Evaluating Qiagen (QGEN) Valuation After Recent Short Term Share Price Recovery - Yahoo Finance
Qiagen N.V. (QGEN) Stock Analysis: Healthcare Innovator With Nearly 20% Upside Potential - DirectorsTalk Interviews
Qiagen N.V. stock (NL0012169213): steady after Q1 2026 update while analysts refine outlook - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): shares steady after Q1 2026 update and ownership shift - AD HOC NEWS
UBS Discloses 2.45% Stake in Qiagen via AFM Notification - The Globe and Mail
Bank of America Discloses 3.15% Voting Stake in Qiagen - The Globe and Mail
Legal & General Group Plc Sells 40,221 Shares of Qiagen N.V. $QGEN - MarketBeat
Qiagen N.V. stock (NL0012169213): UBS stake disclosure and AFM voting rights notice keep insider own - AD HOC NEWS
QIAGEN’s Outlook Reset: Can Digital PCR And Sample Tech Offset QuantiFERON Weakness? - Smartkarma
Qiagen N.V. stock (NL0012169213): New Ebola research assays in focus as valuation metrics come into - AD HOC NEWS
Is QGEN Stock a Hold After the 2026 Outlook Cut and Q1 Miss? - TradingView
Qiagen N.V. stock (NL0012169213): Diagnostics group under scrutiny after investor investigation upda - AD HOC NEWS
QIAGEN Supports Infectious Disease Research and Surveillance Efforts for Bundibugyo Ebolavirus Outbreak - BioSpace
U.S. Sets Up Ebola Quarantine in Kenya - Devdiscourse
Qiagen NV Bolsters Bundibugyo Ebola Research - Devdiscourse
Qiagen N.V. stock (NL0012169213): Diagnostics specialist in focus after latest earnings - AD HOC NEWS
Deutsche Bank Maintains Qiagen NV(QGEN.US) With Buy Rating - 富途牛牛
QIAGEN NV : Buy rating from Deutsche Bank - marketscreener.com
Qiagen N.V. stock (NL0012169213): diagnostics specialist in focus after recent business updates - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Diagnostics player in focus after latest quarterly update - AD HOC NEWS
Norges Bank Discloses 2.44% Stake in QIAGEN - The Globe and Mail
Qiagen stock (NL0012169213): Investor focus turns to growth and margins - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): Focus on diagnostics growth after Capital Markets Day 2024 - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): diagnostics player in focus after solid first-quarter update - AD HOC NEWS
Qiagen N.V. stock (NL0012169213): earnings outlook and diagnostics demand in focus - AD HOC NEWS
Qiagen Nv (QGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.24%
자본화:
|
볼륨(24시간):